Mood disorders in patients with epilepsy: Epidemiology and management
Patients with epilepsy are at high risk for depression because of an incompletely understood combination of factors that may be both psychosocial and neurological. Interictal depression in patients with epilepsy is an undertreated condition, in part because of concern regarding drug interactions and...
Gespeichert in:
Veröffentlicht in: | CNS drugs 2002, Vol.16 (5), p.291-302 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 302 |
---|---|
container_issue | 5 |
container_start_page | 291 |
container_title | CNS drugs |
container_volume | 16 |
creator | HARDEN, Cynthia L GOLDSTEIN, Martin A |
description | Patients with epilepsy are at high risk for depression because of an incompletely understood combination of factors that may be both psychosocial and neurological. Interictal depression in patients with epilepsy is an undertreated condition, in part because of concern regarding drug interactions and the risk of exacerbating seizures with antidepressant treatment. Bipolar disorder is not described as occurring with a higher than expected frequency in the population with epilepsy, but high rates of depression and suicide are well recognised, highlighting the need for more emphasis on antidepressive treatment in this group of at-risk patients. Neurological factors, including site and lateralisation of seizure focus, may be important for the development of depression, with left-sided seizure foci having a higher association with depressive symptoms. Forced normalisation may be a factor in the paradoxical onset of depression in patients with epilepsy whose seizures suddenly become well controlled by anti-seizure treatment. Lowering of folic acid levels by some antiepileptic drugs (AEDs) may also influence the expression of depression in patients with epilepsy. New AEDs continue to emerge as beneficial treatments themselves for mood disorders, with lamotrigine, gabapentin and, to a lesser extent, topiramate having clinical trials data to support their use in patients with bipolar disease. Similar positive data are available for vagal nerve stimulation. Mood effects of AEDs can be complicated, however, as many of these drugs (e.g. tiagabine) have also been reported to cause depression as an adverse effect. Electroconvulsive therapy in depressed patients with epilepsy requires special consideration. The selective serotonin reuptake inhibitors (SSRIs) and antidepressants that act at multiple receptors (e.g. nefazodone, venlafaxine) are the most appropriate treatments for depressed patients with epilepsy. Among these agents, citalopram has a low risk of interactions with AEDs. Bupropion, clomipramine and maprotiline are associated with a greater risk of seizures compared with other antidepressants and consequently should be used with caution in the treatment of depression in patients with epilepsy. |
doi_str_mv | 10.2165/00023210-200216050-00002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71658238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19672870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-8a63d76cc0d84d925f1d9179e4d8b0524f12464a04eff79c21b8f92443d853763</originalsourceid><addsrcrecordid>eNqFkMlOwzAQhi0EoqXwCsgXuAXGS7xwQ1VZpCIucI7c2C5GSRziVKhvT7pAj5zm1-ibRR9CmMANJSK_BQDKKIGMDoEIyCGDTe8IjQmROiOa8eNtppkELkfoLKXPgeBMiFM0IkRrDkSP0ewlRottSLGzrks4NLg1fXBNn_B36D-wa0Pl2rS-w7M2WFeHWMXlGpvG4to0ZunqgT1HJ95UyV3s6wS9P8zepk_Z_PXxeXo_z0rGRZ8pI5iVoizBKm41zT2xevjXcasWkFPuCeWCG-DOe6lLShbKa8o5sypnUrAJut7tbbv4tXKpL-qQSldVpnFxlQo5yFGUqX9BooWkSsIAqh1YdjGlzvmi7UJtunVBoNi4Ln5dF3-ui63rYfRyf2O1qJ09DO7lDsDVHjCpNJXvTFOGdOCYkCAVZz_ohoVP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19672870</pqid></control><display><type>article</type><title>Mood disorders in patients with epilepsy: Epidemiology and management</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>HARDEN, Cynthia L ; GOLDSTEIN, Martin A</creator><creatorcontrib>HARDEN, Cynthia L ; GOLDSTEIN, Martin A</creatorcontrib><description>Patients with epilepsy are at high risk for depression because of an incompletely understood combination of factors that may be both psychosocial and neurological. Interictal depression in patients with epilepsy is an undertreated condition, in part because of concern regarding drug interactions and the risk of exacerbating seizures with antidepressant treatment. Bipolar disorder is not described as occurring with a higher than expected frequency in the population with epilepsy, but high rates of depression and suicide are well recognised, highlighting the need for more emphasis on antidepressive treatment in this group of at-risk patients. Neurological factors, including site and lateralisation of seizure focus, may be important for the development of depression, with left-sided seizure foci having a higher association with depressive symptoms. Forced normalisation may be a factor in the paradoxical onset of depression in patients with epilepsy whose seizures suddenly become well controlled by anti-seizure treatment. Lowering of folic acid levels by some antiepileptic drugs (AEDs) may also influence the expression of depression in patients with epilepsy. New AEDs continue to emerge as beneficial treatments themselves for mood disorders, with lamotrigine, gabapentin and, to a lesser extent, topiramate having clinical trials data to support their use in patients with bipolar disease. Similar positive data are available for vagal nerve stimulation. Mood effects of AEDs can be complicated, however, as many of these drugs (e.g. tiagabine) have also been reported to cause depression as an adverse effect. Electroconvulsive therapy in depressed patients with epilepsy requires special consideration. The selective serotonin reuptake inhibitors (SSRIs) and antidepressants that act at multiple receptors (e.g. nefazodone, venlafaxine) are the most appropriate treatments for depressed patients with epilepsy. Among these agents, citalopram has a low risk of interactions with AEDs. Bupropion, clomipramine and maprotiline are associated with a greater risk of seizures compared with other antidepressants and consequently should be used with caution in the treatment of depression in patients with epilepsy.</description><identifier>ISSN: 1172-7047</identifier><identifier>EISSN: 1179-1934</identifier><identifier>DOI: 10.2165/00023210-200216050-00002</identifier><identifier>PMID: 11994019</identifier><language>eng</language><publisher>Hong Kong: Adis International</publisher><subject>Adult and adolescent clinical studies ; Anticonvulsants - therapeutic use ; Antidepressive Agents - therapeutic use ; Biological and medical sciences ; Comorbidity ; Electric Stimulation Therapy ; Electroconvulsive Therapy ; Epilepsy - epidemiology ; Epilepsy - psychology ; Epilepsy - therapy ; Humans ; Medical sciences ; Miscellaneous ; Mood disorders ; Mood Disorders - epidemiology ; Mood Disorders - psychology ; Mood Disorders - therapy ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Risk Factors</subject><ispartof>CNS drugs, 2002, Vol.16 (5), p.291-302</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c346t-8a63d76cc0d84d925f1d9179e4d8b0524f12464a04eff79c21b8f92443d853763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13670784$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11994019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HARDEN, Cynthia L</creatorcontrib><creatorcontrib>GOLDSTEIN, Martin A</creatorcontrib><title>Mood disorders in patients with epilepsy: Epidemiology and management</title><title>CNS drugs</title><addtitle>CNS Drugs</addtitle><description>Patients with epilepsy are at high risk for depression because of an incompletely understood combination of factors that may be both psychosocial and neurological. Interictal depression in patients with epilepsy is an undertreated condition, in part because of concern regarding drug interactions and the risk of exacerbating seizures with antidepressant treatment. Bipolar disorder is not described as occurring with a higher than expected frequency in the population with epilepsy, but high rates of depression and suicide are well recognised, highlighting the need for more emphasis on antidepressive treatment in this group of at-risk patients. Neurological factors, including site and lateralisation of seizure focus, may be important for the development of depression, with left-sided seizure foci having a higher association with depressive symptoms. Forced normalisation may be a factor in the paradoxical onset of depression in patients with epilepsy whose seizures suddenly become well controlled by anti-seizure treatment. Lowering of folic acid levels by some antiepileptic drugs (AEDs) may also influence the expression of depression in patients with epilepsy. New AEDs continue to emerge as beneficial treatments themselves for mood disorders, with lamotrigine, gabapentin and, to a lesser extent, topiramate having clinical trials data to support their use in patients with bipolar disease. Similar positive data are available for vagal nerve stimulation. Mood effects of AEDs can be complicated, however, as many of these drugs (e.g. tiagabine) have also been reported to cause depression as an adverse effect. Electroconvulsive therapy in depressed patients with epilepsy requires special consideration. The selective serotonin reuptake inhibitors (SSRIs) and antidepressants that act at multiple receptors (e.g. nefazodone, venlafaxine) are the most appropriate treatments for depressed patients with epilepsy. Among these agents, citalopram has a low risk of interactions with AEDs. Bupropion, clomipramine and maprotiline are associated with a greater risk of seizures compared with other antidepressants and consequently should be used with caution in the treatment of depression in patients with epilepsy.</description><subject>Adult and adolescent clinical studies</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Comorbidity</subject><subject>Electric Stimulation Therapy</subject><subject>Electroconvulsive Therapy</subject><subject>Epilepsy - epidemiology</subject><subject>Epilepsy - psychology</subject><subject>Epilepsy - therapy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Mood disorders</subject><subject>Mood Disorders - epidemiology</subject><subject>Mood Disorders - psychology</subject><subject>Mood Disorders - therapy</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Risk Factors</subject><issn>1172-7047</issn><issn>1179-1934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQhi0EoqXwCsgXuAXGS7xwQ1VZpCIucI7c2C5GSRziVKhvT7pAj5zm1-ibRR9CmMANJSK_BQDKKIGMDoEIyCGDTe8IjQmROiOa8eNtppkELkfoLKXPgeBMiFM0IkRrDkSP0ewlRottSLGzrks4NLg1fXBNn_B36D-wa0Pl2rS-w7M2WFeHWMXlGpvG4to0ZunqgT1HJ95UyV3s6wS9P8zepk_Z_PXxeXo_z0rGRZ8pI5iVoizBKm41zT2xevjXcasWkFPuCeWCG-DOe6lLShbKa8o5sypnUrAJut7tbbv4tXKpL-qQSldVpnFxlQo5yFGUqX9BooWkSsIAqh1YdjGlzvmi7UJtunVBoNi4Ln5dF3-ui63rYfRyf2O1qJ09DO7lDsDVHjCpNJXvTFOGdOCYkCAVZz_ohoVP</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>HARDEN, Cynthia L</creator><creator>GOLDSTEIN, Martin A</creator><general>Adis International</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>2002</creationdate><title>Mood disorders in patients with epilepsy: Epidemiology and management</title><author>HARDEN, Cynthia L ; GOLDSTEIN, Martin A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-8a63d76cc0d84d925f1d9179e4d8b0524f12464a04eff79c21b8f92443d853763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Comorbidity</topic><topic>Electric Stimulation Therapy</topic><topic>Electroconvulsive Therapy</topic><topic>Epilepsy - epidemiology</topic><topic>Epilepsy - psychology</topic><topic>Epilepsy - therapy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Mood disorders</topic><topic>Mood Disorders - epidemiology</topic><topic>Mood Disorders - psychology</topic><topic>Mood Disorders - therapy</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HARDEN, Cynthia L</creatorcontrib><creatorcontrib>GOLDSTEIN, Martin A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>CNS drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HARDEN, Cynthia L</au><au>GOLDSTEIN, Martin A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mood disorders in patients with epilepsy: Epidemiology and management</atitle><jtitle>CNS drugs</jtitle><addtitle>CNS Drugs</addtitle><date>2002</date><risdate>2002</risdate><volume>16</volume><issue>5</issue><spage>291</spage><epage>302</epage><pages>291-302</pages><issn>1172-7047</issn><eissn>1179-1934</eissn><abstract>Patients with epilepsy are at high risk for depression because of an incompletely understood combination of factors that may be both psychosocial and neurological. Interictal depression in patients with epilepsy is an undertreated condition, in part because of concern regarding drug interactions and the risk of exacerbating seizures with antidepressant treatment. Bipolar disorder is not described as occurring with a higher than expected frequency in the population with epilepsy, but high rates of depression and suicide are well recognised, highlighting the need for more emphasis on antidepressive treatment in this group of at-risk patients. Neurological factors, including site and lateralisation of seizure focus, may be important for the development of depression, with left-sided seizure foci having a higher association with depressive symptoms. Forced normalisation may be a factor in the paradoxical onset of depression in patients with epilepsy whose seizures suddenly become well controlled by anti-seizure treatment. Lowering of folic acid levels by some antiepileptic drugs (AEDs) may also influence the expression of depression in patients with epilepsy. New AEDs continue to emerge as beneficial treatments themselves for mood disorders, with lamotrigine, gabapentin and, to a lesser extent, topiramate having clinical trials data to support their use in patients with bipolar disease. Similar positive data are available for vagal nerve stimulation. Mood effects of AEDs can be complicated, however, as many of these drugs (e.g. tiagabine) have also been reported to cause depression as an adverse effect. Electroconvulsive therapy in depressed patients with epilepsy requires special consideration. The selective serotonin reuptake inhibitors (SSRIs) and antidepressants that act at multiple receptors (e.g. nefazodone, venlafaxine) are the most appropriate treatments for depressed patients with epilepsy. Among these agents, citalopram has a low risk of interactions with AEDs. Bupropion, clomipramine and maprotiline are associated with a greater risk of seizures compared with other antidepressants and consequently should be used with caution in the treatment of depression in patients with epilepsy.</abstract><cop>Hong Kong</cop><cop>Auckland</cop><pub>Adis International</pub><pmid>11994019</pmid><doi>10.2165/00023210-200216050-00002</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1172-7047 |
ispartof | CNS drugs, 2002, Vol.16 (5), p.291-302 |
issn | 1172-7047 1179-1934 |
language | eng |
recordid | cdi_proquest_miscellaneous_71658238 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adult and adolescent clinical studies Anticonvulsants - therapeutic use Antidepressive Agents - therapeutic use Biological and medical sciences Comorbidity Electric Stimulation Therapy Electroconvulsive Therapy Epilepsy - epidemiology Epilepsy - psychology Epilepsy - therapy Humans Medical sciences Miscellaneous Mood disorders Mood Disorders - epidemiology Mood Disorders - psychology Mood Disorders - therapy Neuropharmacology Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Risk Factors |
title | Mood disorders in patients with epilepsy: Epidemiology and management |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A42%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mood%20disorders%20in%20patients%20with%20epilepsy:%20Epidemiology%20and%20management&rft.jtitle=CNS%20drugs&rft.au=HARDEN,%20Cynthia%20L&rft.date=2002&rft.volume=16&rft.issue=5&rft.spage=291&rft.epage=302&rft.pages=291-302&rft.issn=1172-7047&rft.eissn=1179-1934&rft_id=info:doi/10.2165/00023210-200216050-00002&rft_dat=%3Cproquest_cross%3E19672870%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19672870&rft_id=info:pmid/11994019&rfr_iscdi=true |